## Rainer Freynhagen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4195754/publications.pdf

Version: 2024-02-01

80 papers 7,768 citations

38 h-index 85 g-index

92 all docs 92 docs citations 92 times ranked 6652 citing authors

#	Article	IF	CITATIONS
1	Association of sensory phenotype with quality of life, functionality, and emotional well-being in patients suffering from neuropathic pain. Pain, 2022, 163, 1378-1387.	4.2	9
2	Safety of tapentadol compared with other opioids in chronic pain treatment: network meta-analysis of randomized controlled and withdrawal trials. Current Medical Research and Opinion, 2021, 37, 89-100.	1.9	13
3	Pregabalin for neuropathic pain in primary care settings: recommendations for dosing and titration. Postgraduate Medicine, 2021, 133, 1-9.	2.0	8
4	Contralateral Sensory and Pain Perception Changes in Patients With Unilateral Neuropathy. Neurology, 2021, 97, e389-e402.	1.1	22
5	Cross-cultural adaptation of the painDETECT questionnaire into Brazilian Portuguese. Brazilian Journal of Anesthesiology (Elsevier), 2021, , .	0.4	6
6	Cross-cultural adaptation and validation of the Persian version of the painDETECT questionnaire. Current Medical Research and Opinion, 2021, 37, 2133-2139.	1.9	2
7	No pain, still gain (of function): the relation between sensory profiles and the presence or absence of self-reported pain in a large multicenter cohort of patients with neuropathy. Pain, 2021, 162, 718-727.	4.2	44
8	When to consider "mixed pain� The right questions can make a difference!. Current Medical Research and Opinion, 2020, 36, 2037-2046.	1.9	19
9	Pain thresholds and intensities of CRPS type I and neuropathic pain in respect to sex. European Journal of Pain, 2020, 24, 1058-1071.	2.8	14
10	Response: letter: pure nociceptive pain is very rare. Current Medical Research and Opinion, 2019, 35, 2137-2137.	1.9	4
11	The relationship between the reporting of euphoria events and early treatment responses to pregabalin: an exploratory post-hoc analysis. Journal of Pain Research, 2019, Volume 12, 2577-2587.	2.0	4
12	painPREDICT: first interim data from the development of a new patient-reported pain questionnaire to predict treatment response using sensory symptom profiles. Current Medical Research and Opinion, 2019, 35, 1177-1185.	1.9	16
13	Current understanding of the mixed pain concept: a brief narrative review. Current Medical Research and Opinion, 2019, 35, 1011-1018.	1.9	119
14	Sensory symptom profiles differ between trigeminal and thoracolumbar postherpetic neuralgia. Pain Reports, 2018, 3, e636.	2.7	9
15	Mixed-methods development of a new patient-reported outcome instrument for chronic low back pain: part 1â€"the Patient Assessment for Low Back Pain - Symptoms (PAL-S). Pain, 2018, 159, 1045-1055.	4.2	13
16	Clinical Manifestation of Acute, Subacute, and Chronic Low Back Pain in Different Age Groups: Low Back Pain in 35,446 Patients. Pain Practice, 2018, 18, 1011-1023.	1.9	14
17	Mixed-methods development of a new patient-reported outcome instrument for chronic low back pain: part 2â€"The Patient Assessment for Low Back Painâ€"Impacts (PAL-I). Pain, 2018, 159, 2066-2075.	4.2	7
18	Pain Drawings Improve Subgrouping of Low Back Pain Patients. Pain Practice, 2017, 17, 293-304.	1.9	22

#	Article	IF	CITATIONS
19	Treatment of painful radiculopathies with capsaicin 8% cutaneous patch. Current Medical Research and Opinion, 2017, 33, 1401-1411.	1.9	13
20	Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles. Pain, 2017, 158, 261-272.	4.2	462
21	Stratifying patients with peripheral neuropathic pain based on sensory profiles: algorithm and sample size recommendations. Pain, 2017, 158, 1446-1455.	4.2	150
22	Assessment of Patient-Reported Outcome Instruments to Assess Chronic Low Back Pain. Pain Medicine, 2017, 18, 1098-1110.	1.9	43
23	Neuropathic pain in cancer: systematic review, performance of screening tools and analysis of symptom profiles. British Journal of Anaesthesia, 2017, 119, 765-774.	3.4	38
24	Cebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain in a randomized clinical trial. Pain, 2017, 158, 1813-1824.	4.2	78
25	Emergent biomarker derived from next-generation sequencing to identify pain patients requiring uncommonly high opioid doses. Pharmacogenomics Journal, 2017, 17, 419-426.	2.0	25
26	Symptom profiles in the painDETECT Questionnaire in patients with peripheral neuropathic pain stratified according to sensory loss in quantitative sensory testing. Pain, 2016, 157, 1810-1818.	4.2	29
27	Are there different predictors of analgesic response between antidepressants and anticonvulsants in painful diabetic neuropathy?. European Journal of Pain, 2016, 20, 472-482.	2.8	28
28	Quantitative sensory testing using DFNS protocol in Europe. Pain, 2016, 157, 750-758.	4.2	71
29	Pregabalin for the Treatment of Drug and Alcohol Withdrawal Symptoms: A Comprehensive Review. CNS Drugs, 2016, 30, 1191-1200.	5.9	39
30	A retrospective analysis of the long-term testâ€"retest stability of pain descriptors of the painDETECT questionnaire. Current Medical Research and Opinion, 2016, 32, 343-349.	1.9	21
31	The painDETECT project – far more than a screening tool on neuropathic pain. Current Medical Research and Opinion, 2016, 32, 1033-1057.	1.9	141
32	Neuropathic pain phenotyping by international consensus (NeuroPPIC) for genetic studies. Pain, 2015, 156, 2337-2353.	4.2	86
33	Who is healthy? Aspects to consider when including healthy volunteers in QST-based studies—a consensus statement by the EUROPAIN and NEUROPAIN consortia. Pain, 2015, 156, 2203-2211.	4.2	53
34	A Comprehensive Drug Safety Evaluation of Pregabalin in Peripheral Neuropathic Pain. Pain Practice, 2015, 15, 47-57.	1.9	61
35	Neuropathic pain phenotyping as a predictor of treatment response in painful diabetic neuropathy: Data from the randomized, double-blind, COMBO-DN study. Pain, 2014, 155, 2171-2179.	4.2	109
36	The role of screening tools in diagnosing neuropathic pain. Pain Management, 2014, 4, 233-243.	1.5	33

3

#	Article	IF	CITATIONS
37	Crossâ€Cultural Adaptation to the Dutch Language of the Pain <i>DETECTâ€</i> Questionnaire. Pain Practice, 2013, 13, 206-214.	1.9	39
38	Mechanism- and experience-based strategies to optimize treatment response to the capsaicin 8% cutaneous patch in patients with localized neuropathic pain. Current Medical Research and Opinion, 2013, 29, 527-538.	1.9	60
39	Duloxetine and pregabalin: High-dose monotherapy or their combination? The "COMBO-DN study―– a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain, 2013, 154, 2616-2625.	4.2	227
40	Opioids for chronic non-cancer pain. BMJ, The, 2013, 346, f2937-f2937.	6.0	34
41	Axial Low Back Pain: One Painful Area – Many Perceptions and Mechanisms. PLoS ONE, 2013, 8, e68273.	2.5	72
42	Hereditary Sensory and Autonomic Neuropathy With Autonomic Crises. Journal of Child Neurology, 2012, 27, 191-196.	1.4	4
43	Sensory Symptom Profiles and Co-Morbidities in Painful Radiculopathy. PLoS ONE, 2011, 6, e18018.	2.5	72
44	Fibromyalgia and neuropathic pain - differences and similarities. A comparison of 3057 patients with diabetic painful neuropathy and fibromyalgia. BMC Neurology, 2011, 11, 55.	1.8	127
45	Higher pain scores, similar opioid doses and side effects associated with antipyretic analgesics in specialised tertiary pain care. Inflammation Research, 2010, 59, 989-995.	4.0	6
46	The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy. Pain, 2010, 150, 420-427.	4.2	132
47	Differential Effects of Painful and Non-Painful Stimulation on Tactile Processing in Fibromyalgia Syndrome and Subjects with Masochistic Behaviour. PLoS ONE, 2010, 5, e15804.	2.5	10
48	A cross-sectional survey of 3035 patients with fibromyalgia: subgroups of patients with typical comorbidities and sensory symptom profiles. Rheumatology, 2010, 49, 1146-1152.	1.9	128
49	Efficacy and Safety of Lacosamide in Painful Diabetic Neuropathy. Diabetes Care, 2010, 33, 839-841.	8.6	83
50	Ziconotide for treatment of severe chronic pain. Lancet, The, 2010, 375, 1569-1577.	13.7	306
51	A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: Differences in demographic data and sensory symptoms. Pain, 2009, 146, 34-40.	4.2	270
52	Antinociceptive effects of systemic lidocaine: Involvement of the spinal glycinergic system. European Journal of Pharmacology, 2009, 613, 68-73.	3.5	65
53	The evaluation of neuropathic components in low back pain. Current Pain and Headache Reports, 2009, 13, 185-190.	2.9	208
54	Modelling the prevalence and cost of back pain with neuropathic components in the general population. European Journal of Pain, 2009, 13, 1030-1035.	2.8	82

#	Article	IF	CITATIONS
55	Racemic intrathecal mirtazapine but not its enantiomers acts anti-neuropathic after chronic constriction injury in rats. Brain Research Bulletin, 2009, 79, 63-68.	3.0	6
56	Diagnosis and management of neuropathic pain. BMJ: British Medical Journal, 2009, 339, b3002-b3002.	2.3	146
57	Cross-sectional Assessment of the Consequences of a GTP Cyclohydrolase 1 Haplotype for Specialized Tertiary Outpatient Pain Care. Clinical Journal of Pain, 2009, 25, 781-785.	1.9	32
58	Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenetics and Genomics, 2009, 19, 429-436.	1.5	106
59	Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: A randomized, doubleâ€blind study. European Journal of Pain, 2008, 12, 203-213.	2.8	190
60	Pseudoradicular and radicular low-back pain $\hat{a} \in A$ disease continuum rather than different entities? Answers from quantitative sensory testing. Pain, 2008, 135, 65-74.	4.2	140
61	Pseudoradicular and radicular low-back pain $\hat{a} \in A$ disease continuum rather than different entities? Reply to the letters by Leffler and Hansson and by Van Boxem et al Pain, 2008, 135, 313-315.	4.2	3
62	Pseudoradicular and radicular low-back pain – A disease continuum rather than different entities? Rebuttal: Reply to the letter "Cheese and Chalk? Missing the real anatomy―by Breck McKay. Pain, 2008, 137, 229-231.	4.2	2
63	Pseudoradicular and radicular low-back pain $\hat{a} \in A$ disease continuum rather than different entities? Rebuttal: Reply to the letter by M. Schiltenwolf and M. Akbar. Pain, 2008, 138, 689-690.	4.2	0
64	Racemic mirtazapine but not its enantiomers acts antinociceptive in experimental neuropathic pain. European Journal of Anaesthesiology, 2008, 25, 194.	1.7	0
65	Paper versus electronic rating scales for pain assessment: a prospective, randomised, cross-over validation study with 200 chronic pain patients. Current Medical Research and Opinion, 2008, 24, 1797-1806.	1.9	48
66	Hydromorphone-induced hyperalgesia in a patient with metastatic pancreatic cancer. The Pain Clinic, 2007, 19, 109-111.	0.1	0
67	Using screening tools to identify neuropathic pain. Pain, 2007, 127, 199-203.	4.2	462
68	Uniform Distribution of Skin-Temperature Increase After Different Regional-Anesthesia Techniques of the Lower Extremity. Regional Anesthesia and Pain Medicine, 2007, 32, 73-78.	2.3	27
69	Regeneration of baroafferents after implantation into different vessels. Journal of the Peripheral Nervous System, 2007, 12, 40-49.	3.1	1
70	Efficacy and safety of pregabalin in treatment refractory patients with various neuropathic pain entities in clinical routine. International Journal of Clinical Practice, 2007, 61, 1989-1996.	1.7	38
71	Nitric oxide and pro-inflammatory cytokines correlate with pain intensity in chronic pain patients. Inflammation Research, 2007, 56, 32-37.	4.0	165
72	Increase in Skin Temperature After Spinal Anesthesia in Infants. Regional Anesthesia and Pain Medicine, 2006, 31, 519-522.	2.3	1

#	Article	IF	CITATIONS
73	Fatal Respiratory Depression after??Multiple Intravenous Morphine Injections. Clinical Pharmacokinetics, 2006, 45, 1051-1060.	3.5	75
74	Mirtazapine and its enantiomers differentially modulate acute thermal nociception in rats. Brain Research Bulletin, 2006, 69, 168-173.	3.0	10
75	pain <i>DETECT</i> : a new screening questionnaire to identify neuropathic components in patients with back pain. Current Medical Research and Opinion, 2006, 22, 1911-1920.	1.9	1,747
76	Imaging Pain Modulation by Subanesthetic S-(+)-Ketamine. Anesthesia and Analgesia, 2006, 103, 729-737.	2.2	66
77	The effect of mirtazapine in patients with chronic pain and concomitant depression. Current Medical Research and Opinion, 2006, 22, 257-264.	1.9	40
78	Screening of neuropathic pain components in patients with chronic back pain associated with nerve root compression: a prospective observational pilot study (MIPORT). Current Medical Research and Opinion, 2006, 22, 529-537.	1.9	127
79	Switching from Reservoir to Matrix Systems for the Transdermal Delivery of Fentanyl: A Prospective, Multicenter Pilot Study in Outpatients with Chronic Pain. Journal of Pain and Symptom Management, 2005, 30, 289-297.	1.2	41
80	Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain, 2005, 115, 254-263.	4.2	488